Variety of eligible individuals: CDEC discussed the uncertainty in the number of patients with reasonably critical to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some people that are categorized as getting mild or average ailment might have a severe bleeding phenotype, https://hemgenix50482.tribunablog.com/fascination-about-hemgenix-50268018